OncoMatch/Clinical Trials/NCT06791148
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
Is NCT06791148 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including albumin-bound paclitaxel and AK112 for gastric cancer.
Treatment: albumin-bound paclitaxel · AK112 — The study aims to evaluate the efficacy and safety of the combination of albumin-bound paclitaxel and AK112 with low-dose radiotherapy in patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed first-line standard therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Gastric Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard treatment — first-line
failed first-line standard treatment
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Platelets ≥ 90 x 10^9/L; Hemoglobin ≥ 80 g/L
Kidney function
Serum creatinine ≤ 1.5x ULN and creatinine clearance ≥ 60 ml/min
Liver function
Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN
Cardiac function
Cardiac enzyme levels within normal range (minor lab abnormalities deemed not clinically significant by the investigator are allowed)
Adequate organ function is determined by the following criteria: ANC ≥ 1.5 x 10^9/L; Platelets ≥ 90 x 10^9/L; Hemoglobin ≥ 80 g/L; Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN; Serum creatinine ≤ 1.5x ULN and creatinine clearance ≥ 60 ml/min; Good coagulation function, defined as INR or PT ≤ 1.5x ULN; Cardiac enzyme levels within normal range (minor lab abnormalities deemed not clinically significant by the investigator are allowed)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06791148 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard treatment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages